Two New Studies Demonstrate Advantages of Andrew Technologies’ HydraSolve® as the Company Heads to ASPS 2016

TUSTIN, Calif.–(BUSINESS WIRE)–Andrew Technologies, LLC today announced the first published clinical
study of HydraSolve for breast reconstruction and the availability of
new clinical data comparing HydraSolve to suction-assisted liposuction
(SAL) as it prepares to attend the American Society of Plastic Surgery
(ASPS) meeting this week in Los Angeles.

The HydraSolve study titled, “Fat Grafting with Tissue Liquefaction
Technology™ (TLT) as an Adjunct to Breast Reconstruction,” will appear
in the December issue of Aesthetic Plastic Surgery and is
currently available online. In this retrospective study, researchers at
Washington University in St. Louis reviewed the charts of 136
consecutive patients who underwent TLT subsequently used in 237 breast
reconstructions, evaluating donor and recipient site complications. The
overall complication rate at the recipient site was 28.7%, however the
clinically evident rate of fat necrosis was only 6.3% per treated
breast. Bruising (ecchymosis) was the primary donor site complication,
with 71.1% experiencing minimal bruising and widespread bruising
occurring in only 10.4% of patients.

“We concluded that TLT with HydraSolve is very different from other fat
harvesting modalities,” explains one of the study’s principle
investigators Dr. Marissa Tenenbaum. “Although donor and recipient site
complications are similar to other methods used to harvest adipocytes
for fat transfer, the quality of the harvested fat and the procedure’s
efficiency make HydraSolve a sound option.”

Thirty-one patients have now been treated by five plastic surgeons in
the new study titled, “A Multicenter, Prospective, Randomized,
Single-Blinded, Controlled Clinical Trial of HydraSolve vs.
Suction-Assisted Liposuction.” The investigators found that after the
procedure, the sites treated with HydraSolve had reduced bruising,
swelling and treatment site tenderness compared to the sites treated
with SAL. HydraSolve’s fat extraction rate was 40.4% more efficient than
SAL, and surgeons’ cannula stroke rate was 65% lower with HydraSolve.
Surgeons’ satisfaction rating for HydraSolve was higher than SAL, and
they found it required less exertion. The study will be submitted to a
leading plastic surgery journal later this year.

“We were encouraged to find such a clear advantage to the tissue
liquefaction approach from both the patients’ and surgeons’
perspectives,” says study author Dr. Bill G. Kortesis of Hunstad
Kortesis in Huntersville, N.C. “Recovery is so important to our
patients’ wellbeing and their satisfaction with surgery, so it is
exciting to see the potential for a more comfortable experience. The
fact that surgeons are able to achieve these outcomes with greater speed
and comfort in the OR makes HydraSolve a logical choice.”

Andrew Technologies Chairman and CEO Tom Albright adds, “Breast
reconstruction following successful treatment for breast cancer is one
of the most important applications of HydraSolve. We take great pride in
offering patients a natural solution with safe, effective fat transfer.
HydraSolve’s low complication rates and more comfortable recovery allow
patients to get back to their lives after cancer.”

Attendees at the American Society of Plastic Surgeons (ASPS) Plastic
Surgery Expo September 24, 10 a.m. to 6 p.m., in Los Angeles can learn
more about HydraSolve by visiting Andrew Technologies at Booth #1531 in
the Los Angeles Convention Center.

About HydraSolve

HydraSolve is a novel liposuction device based on the proprietary
surgical innovation, Tissue Liquefaction Technology™ (TLT), which
combines natural saline solution with low levels of temperature and
pressure to liquefy only targeted fat tissue. Because fat tissue is
liquefied, the cutting of fat by forceful thrusts of the cannula is no
longer required. HydraSolve is the first liposuction device
FDA cleared for autologous fat transfer. The device is primarily used to
transfer fat for breast reconstruction following breast cancer treatment
and is not intended for treatment of obesity. Fat transfer and
liposuction are surgical procedures that have risks similar to other
cosmetic surgeries. For more information, please go to www.hydrasolve.com.

About Andrew Technologies, LLC

Andrew Technologies, LLC, is a privately funded medical technology
company committed to improving patients’ lives through precision
surgery. Founded in 2007, Andrew received FDA clearance for HydraSolve
in 2012. HydraSolve is primarily used to transfer fat for breast
reconstruction following breast cancer treatment. In addition to
HydraSolve, Andrew has an impressive research pipeline that includes
minimally invasive surgery to correct type 2 diabetes and adipose stem
cell isolation.

Contacts

Public Relations:
Pascale Communications
Amy Phillips,
412-327-9499
amy@pascalecommunications.com